128 terminated. 128 Phase 2, 15 Phase 1, 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 128 | Terminated 128 |
| Phase 1 | 15 | Terminated 15 |
| Phase 3 | 14 | Terminated 14 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium | Phase 2 | Terminated | University of Missouri-Columbia | 1 | 2026-03-03 | 2026-05-11 |
| Extension Study of Participants From SPG302-ALZ-101 SPG302 - Alzheimer's Disease | Phase 2 | Terminated | Spinogenix | 12 | 2025-03-25 | 2025-12-18 |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) MK-1167, Placebo - Alzheimer Disease, Dementia | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 369 | 2024-12-16 | 2026-07-01 |
| Study of ASN51 in Adults With Early Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 2 | Terminated | Asceneuron S.A. | 123 | 2024-10-16 | 2025-06-29 |
| Ultrasonic Neuromodulation for Treatment of Cognitive Impairment Diadem prototype - Alzheimer Disease, Dementia | Phase 1 / Phase 2 | Terminated | University of Utah | 1 | 2024-08-18 | 2025-05-25 |
| Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients SHR-1707, SHR-1707 placebo - Alzheimer's Disease | Phase 2 | Terminated | Shanghai Hengrui Pharmaceutical Co., Ltd. | 46 | 2024-02-05 | 2026-05-13 |
| A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. PrimeC, Placebo - Alzheimer Disease | Phase 2 | Terminated | NeuroSense Therapeutics Ltd. | 8 | 2023-11-19 | 2026-04-09 |
| Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease GSK4527226, Placebo - Alzheimer's Disease | Phase 2 | Terminated | GlaxoSmithKline | 367 | 2023-10-20 | 2026-09-17 |
| Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) Methylprednisolone - Post-COVID-19 Syndrome | Phase 2 | Terminated | Charite University, Berlin, Germany | 96 | 2023-10-01 | 2026-05-05 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease XPro1595 - Alzheimer Disease, Dementia | Phase 2 | Terminated | Inmune Bio, Inc. | 11 | 2023-02-21 | 2026-02-27 |
| A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease AL002 - Alzheimer's Disease | Phase 2 | Terminated | Alector Inc. | 197 | 2023-01-04 | 2026-02-25 |
| Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) WVE-004 10 mg Q12W - Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 8 | 2022-12-14 | 2026-09-09 |
| Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) MK-1942, Placebo - Alzheimer's Disease | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 99 | 2022-12-02 | 2024-12-10 |
| Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease Wei Li Bai capsules, Placebo Comparator of Wei Li Bai capsules - Alzheimer Disease | Phase 2 | Terminated | Capital Medical University | 105 | 2022-10-01 | 2024-12-04 |
| A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease TB006 - Alzheimer's Disease | Phase 2 | Terminated | TrueBinding, Inc. | 119 | 2022-09-15 | 2026-05-06 |
| Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease Piromelatine 20 mg, Placebo - Alzheimer's Disease | Phase 2 / Phase 3 | Terminated | Neurim Pharmaceuticals Ltd. | 216 | 2022-06-15 | 2026-09-09 |
| A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease REM0046127 High Dose, REM0046127 Low Dose, Placebo - Alzheimer Disease | Phase 2 | Terminated | reMYND | 14 | 2022-06-07 | 2025-12-03 |
| Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease simufilam - Alzheimer's Disease | Phase 2 | Terminated | Cassava Sciences, Inc. | 90 | 2022-05-12 | 2025-08-15 |
| An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia BXCL501, Placebo film - Agitation, Dementia | Phase 2 | Terminated | BioXcel Therapeutics Inc | 5 | 2022-02-08 | 2026-08-11 |
Showing 20 of 128. Sign in to see all of them.
Alzheimer Disease (84) · Dementia (22) · Cognitive Dysfunction (21) · Huntington Disease (11) · Cognition Disorders (6) · Brain Diseases (5) · Schizophrenia (5) · Inflammation (4) · Lewy Body Disease (4) · Mental Disorders (4) · Nervous System Diseases (4) · Psychomotor Agitation (4) · Central Nervous System Diseases (3) · Delirium (3)
Mental Disorders (124) · Nervous System Diseases (110) · Central Nervous System Diseases (106) · Brain Diseases (104) · Neurodegenerative Diseases (100) · Dementia (86) · Tauopathies (81) · Cognition Disorders (31) · Pathological Conditions, Signs and Symptoms (22) · Basal Ganglia Diseases (16) · Movement Disorders (16) · Signs and Symptoms (16) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Dyskinesias (14)
Donepezil (5) · Insulin (3) · pozanicline (3) · ABT-126 (2) · Magnetic Resonance Spectroscopy (2) · Umibecestat (2) · atabecestat (2) · bapineuzumab (2) · gantenerumab (2) · talsaclidine fumarate (2) · vanutide cridificar (2) · (18F)GTP1 (1) · 2-Hydroxypropyl-beta-cyclodextrin (1) · 3-(5-chloro-2-furoyl)-3,7-diazabicyclo(3.3.0)octane (1) · 3-benzenesulfonyl-8-piperazin-1-ylquinoline (1)
Pfizer (6) · Merck Sharp & Dohme LLC (5) · Novartis Pharmaceuticals (5) · Wave Life Sciences USA, Inc. (5) · Abbott (3) · Janssen Research & Development, LLC (3) · AbbVie (2) · AbbVie (prior sponsor, Abbott) (2) · AstraZeneca (2) · Axovant Sciences Ltd. (2) · Biogen (2) · Boehringer Ingelheim (2) · Eli Lilly and Company (2) · Epix Pharmaceuticals, Inc. (2) · GlaxoSmithKline (2)
United States (87) · Canada (36) · United Kingdom (30) · Germany (26) · France (24) · Spain (23) · Australia (22) · Netherlands (14) · Italy (13) · Poland (13) · Japan (11) · Belgium (9) · Denmark (9) · Sweden (8) · Finland (7)
Ilise Lombardo, MD (2) · Laura Gault, MD (2) · Michael H Rosenbloom, MD (2) · A Keegan, MD (1) · Aaron R Ritter, MD (1)
PMID 29480210, PMID 32250312, PMID 40603145, PMID 25669746, PMID 25689146, PMID 25887557, PMID 25973909, PMID 26414022, PMID 26967214, PMID 27756421, PMID 27767991, PMID 27807285, PMID 27871675, PMID 28705532, PMID 29622037, PMID 29719179, PMID 29884231, PMID 29955661, PMID 30129411, PMID 30572891, PMID 31387606, PMID 31518224, PMID 31764959, PMID 32410694, PMID 33049114, PMID 33252075, PMID 33253354, PMID 33464300, PMID 33719017, PMID 33974419, PMID 35384522, PMID 35696185, PMID 35794343, PMID 36463457, PMID 36641609, PMID 36671553, PMID 37280688, PMID 37325545, PMID 38012285, PMID 38489195, PMID 38599894, PMID 38606196, PMID 39350369, PMID 39513754, PMID 39559869, PMID 39974075, PMID 40120616, PMID 40216220, PMID 40375477, PMID 40937833
2014 (5), 2015 (4), 2009 (2), 2016 (2), 2017 (2), 2018 (2), 1UF1AG046150-01 (1), 2023 (1), K23AG052633 (1), R01AG046179 (1), R01AG053267 (1), R01AG061146 (1), R21AT005510 (1), R56AG053267 (1), U01AG042791 (1)